These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 2107997

  • 1. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 2. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N, Pohl J.
    IARC Sci Publ; 1986 Mar; (78):269-79. PubMed ID: 3108156
    [Abstract] [Full Text] [Related]

  • 3. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Mar; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL, Brogden RN, Pilkington T, Faulds D.
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [Abstract] [Full Text] [Related]

  • 5. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF, Budd GT.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [Abstract] [Full Text] [Related]

  • 7. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N.
    Recent Results Cancer Res; 1980 Jun 01; 74():270-8. PubMed ID: 6777836
    [Abstract] [Full Text] [Related]

  • 8. Ifosfamide in non-small cell lung cancer.
    Johnson DH.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):7-10. PubMed ID: 8677453
    [Abstract] [Full Text] [Related]

  • 9. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD, Talle K.
    Cancer Treat Rep; 1980 Jun 01; 64(10-11):1103-8. PubMed ID: 6780190
    [Abstract] [Full Text] [Related]

  • 10. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.
    Cancer; 2003 Jul 15; 98(2):331-6. PubMed ID: 12872353
    [Abstract] [Full Text] [Related]

  • 11. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H, Schnitker J, Fichtner E.
    MMW Munch Med Wochenschr; 1979 Jun 01; 121(22):760-2. PubMed ID: 112422
    [Abstract] [Full Text] [Related]

  • 12. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H, Konarski L, Kowalski P, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1997 Jun 01; 45(1):79-85. PubMed ID: 9090445
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide and Mesna in advanced malignancies.
    Li GC, Brock N, Li JQ, Guan ZZ, He YJ.
    Chin Med J (Engl); 1988 Mar 01; 101(3):213-20. PubMed ID: 3136996
    [No Abstract] [Full Text] [Related]

  • 14. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Pratt CB, Douglass EC, Etcubanas E, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA.
    Semin Oncol; 1989 Feb 01; 16(1 Suppl 3):51-5. PubMed ID: 2495567
    [Abstract] [Full Text] [Related]

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 16. Oral administration of mesna with ifosfamide.
    Goren MP.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide and mesna in epithelial ovarian carcinoma.
    Sutton G.
    Gynecol Oncol; 1993 Oct 01; 51(1):104-8. PubMed ID: 8244163
    [Abstract] [Full Text] [Related]

  • 18. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1989 Feb 01; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [Abstract] [Full Text] [Related]

  • 19. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.